Ecallantide (J1290) for Acute Hereditary Angioedema — Coverage Criteria
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical benefit coverage criteria, quantity limits, and authorization period for ecallantide (injection) used to treat acute attacks of hereditary angioedema for members of Community-Care.
No material clinical or coverage changes in this revision.
Coverage Criteria for Ecallantide
Initial Therapy — Covered when ALL of the following are met
Covered when ALL of the following are met
Acute hereditary angioedema coverage criteria
Prescribing and diagnosis
- Prescribed by, or in consultation with, an allergist or immunologist
- Confirmed diagnosis of hereditary angioedema
Prior therapy
- Trial of icatibant (Firazyr) was ineffective, contraindicated, or not tolerated
Operational requirement
- Medication is required to be on hand for acute treatment
None specified beyond the listed criteria.
No additional exclusions or not-medically-necessary statements are specified in this policy beyond the coverage criteria and requirements already listed.
Applicable Codes
| J1290 | Injection, ecallantide, 1 mg |
Provider Requirements and Authorization Rules
Prior Authorization Required
Prior authorization is required for ecallantide (HCPCS J1290) for treatment of acute hereditary angioedema (HAE) attacks. Requests must document the indication, that the medication will be available for acute use, and meet the clinical criteria below.
- Affected code: J1290 — Injection, ecallantide, 1 mg
- Authorization period: up to 1 year if approved
Step Therapy: Icatibant Trial Required
A prior trial of icatibant (Firazyr) is required and must have been ineffective, contraindicated, or not tolerated before ecallantide will be authorized. If icatibant cannot be used for clinical reasons, documentation must explain the specific contraindication or intolerance.
- Step requirement: documented trial of icatibant (Firazyr) OR documentation of contraindication/intolerance/ineffectiveness
Required Documentation
Documentation must confirm a diagnosis of hereditary angioedema and show that the prescriber is an allergist or immunologist, or that the treating prescriber consulted with an allergist/immunologist. Include clinical history of HAE attacks, prior therapies tried (including icatibant), and rationale for ecallantide.
- Required documentation: confirmed HAE diagnosis
- Prescriber requirement: prescribing clinician must be an allergist/immunologist or include documented consultation with one
- Clinical details: attack history and prior treatment response
Triggers for Denial
Authorization may be denied if required documentation is missing or incomplete. Common triggers for denial include lack of confirmed HAE diagnosis, absence of documentation of icatibant trial or valid contraindication/intolerance, and prescribing by a clinician who is not a specialist without documented consultation.
- Denial triggers: no confirmed HAE diagnosis
- Denial triggers: no documentation of icatibant trial or documented contraindication/intolerance
- Denial triggers: prescriber is not an allergist/immunologist and no consultation is documented
Background
Hereditary angioedema is characterized by recurrent acute attacks of swelling that may require on-demand treatment. Ecallantide is an injectable therapy indicated for treatment of acute attacks and is covered when specified criteria are met, including that it be prescribed by or in consultation with an allergist or immunologist, the member has a confirmed diagnosis of hereditary angioedema, a trial of icatibant (Firazyr) was ineffective, contraindicated, or not tolerated, and the medication will be kept on-hand for acute treatment.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.